Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance

Journal of Diabetes Investigation

Volumn 9, Issue 4, 2018, Pages 870-874

  Hattori, Sachiko ^a  

^a Tohto Clinic   (Japan)

Author keywords

Insulin resistance; Remnant lipoprotein; Sodium glucose cotransporter 2 inhibitor

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; EMPAGLIFLOZIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; REMNANT LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CHOLESTEROL; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN; REMNANT-LIKE PARTICLE CHOLESTEROL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC PATIENT; DRUG EFFECT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TIME TO TREATMENT; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; BLOOD; COMPLICATION; GLUCOSE BLOOD LEVEL; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPOPROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 85050010908     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12781     Document Type: Article

References (15)

1. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015; 75: 33–59
2. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015; 12: 90–100
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128
4. Iozzo P, Chareonthaitawee P, Dutka D, et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002; 51: 3020–3024
5. Okazaki M, Usui S, Tada N, et al. Relation between RLP-triglyceride to RLP-cholesterol ratio and particle size distribution in RLP-cholesterol profiles by HPLC. Clin Chim Acta 2000; 296: 135–149
6. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–458
7. Schaefer EJ, McNamara JR, Shah PK, et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002; 25: 989–994
8. Chan DC, Watts GF, Barrett PH, et al. Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clin Sci (Lond) 2003; 104: 383–388
9. Ohnishi H, Saitoh S, Takagi S, et al. Relationship between insulin-resistance and remnant-like particle cholesterol. Atherosclerosis 2002; 164: 167–170
10. Abbasi F, McLaughlin T, Lamendola C, et al. Fasting remnant lipoprotein cholesterol and triglyceride concentrations are elevated in nondiabetic, insulin-resistant, female volunteers. J Clin Endocrinol Metab 1999; 84: 3903–3906
11. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499–508
12. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509–514
13. Yamamoto S, Tomoyasu M, Osamura A, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol 2017; 16: 8
14. Kugiyama K, Doi H, Takazoe K, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858–2860
15. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis Diabetes Care 2016; 39: 1115–1122